A trial picked the patients most likely to favour abatacept. They didn't.

Rheumatology has spent a decade chasing the promise of precision medicine: matching the right biologic to the right patient instead of trying drugs in sequence. Earlier evidence had hinted that abatacept, which dampens T-cell activation, works especially well in patients whose blood carries certain autoantibodies. A large industry-funded trial set out to confirm that by deliberately enrolling the patients in whom abatacept should have the clearest edge — and then found no edge at all [s1].

The hypothesis the trial was built to test

The AMPLIFIED trial, registered as NCT04909801 and funded by Bristol-Myers Squibb, which markets abatacept, was designed around a specific prediction [s1][s2]. Its investigators enrolled adults with early rheumatoid arthritis who had responded inadequately to methotrexate and who carried a cluster of biological risk markers: dual seropositivity for anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF), plus the HLA-DRB1 "shared epitope" risk allele [s1]. This is the profile in which abatacept's mechanism was thought most likely to outperform a tumour necrosis factor (TNF) inhibitor. The comparator was adalimumab, one of the most widely used TNF inhibitors in the world.

The two drugs attack the disease from different angles. Abatacept is a fusion protein that interrupts the activation of T cells, one of the earliest steps in the immune cascade of rheumatoid arthritis; adalimumab blocks TNF, a downstream inflammatory messenger. Retrospective and mechanistic work had suggested that patients with the antibody-and-genetic profile AMPLIFIED selected for might respond better to interrupting that upstream T-cell step — a reasonable hypothesis, and exactly the kind that a prospective head-to-head trial exists to test [s1].

AMPLIFIED was a global, phase 3, head-to-head, randomised, single-blind study [s1]. The primary endpoint was a 50% improvement on the American College of Rheumatology criteria — known as ACR50 — at week 24, measured in the shared-epitope-positive subgroup [s1]. In other words, the trial asked whether, in exactly the patients predicted to favour abatacept, abatacept would in fact win.

What it found

It did not. In total 338 patients were randomised, and 96% completed treatment [s1]. The primary endpoint was not met: ACR50 at week 24 was 59% with abatacept and 60% with adalimumab, an adjusted odds ratio of 1.0 (95% confidence interval 0.6 to 1.6) — as close to identical as two drugs can be [s1]. Laboratory markers moved in parallel too: levels of anti-cyclic citrullinated peptide 2, C-reactive protein and rheumatoid factor fell with both treatments, and both improved patient-reported outcomes including pain [s1].

The trial did detect differences beneath the surface. Abatacept and adalimumab had distinct effects on immune modulation, including on B-cell homeostasis — a biological fingerprint that the two drugs work differently even when the clinical result converges [s1]. Safety was similar: adverse events occurred in 58.0% of abatacept patients and 59.2% of adalimumab patients, and serious adverse events in 2.4% and 3.6%, respectively [s1].

How to read it

A negative primary endpoint is not a failed trial; it is an answer. AMPLIFIED's answer is that even a carefully selected, biomarker-enriched population did not single out abatacept as the better choice over adalimumab at six months [s1]. That is useful precisely because the deck was stacked in abatacept's favour by design. When a drug's maker funds a trial engineered to show that drug at its best, and the result is a dead heat, the null carries weight [s1].

The usual limits apply. The primary comparison was at week 24, so this says nothing about longer-term divergence, radiographic joint damage over years, or what happens to patients who fail one drug and switch to the other [s1]. The study was single-blind rather than double-blind, a design choice that can introduce bias in subjective measures, though the parallel movement of objective blood markers is reassuring [s1]. And the enrolled population was narrow by construction — early disease, specific antibody and genetic markers — so the finding should not be stretched to every patient with rheumatoid arthritis [s1][s2]. The differing effects on B cells leave open the possibility that the drugs diverge on outcomes this trial did not primarily measure [s1].

What to watch

The practical takeaway is that, for this early and seropositive group, both remain reasonable first-biologic options, and the choice can turn on other factors — route of administration, cost, comorbidities — rather than a presumed efficacy gap [s1]. The open scientific question is whether the distinct immune signatures translate into any long-term difference in disease course, which would need extended follow-up to settle [s1][s2]. This article describes research and is not medical advice; treatment decisions in rheumatoid arthritis belong with a rheumatologist.

Sources

• A head-to-head comparison of abatacept and adalimumab in early, dual-seropositive rheumatoid arthritis: the randomised phase 3 AMPLIFIED trial — Annals of the Rheumatic Diseases, 10 July 2026
• A Study to Compare the Response to Treatment With Abatacept vs Adalimumab in Early Rheumatoid Arthritis (NCT04909801) — ClinicalTrials.gov